Cathy Yarbrough

Cathy Yarbrough

For over 25 years, Cathy Yarbrough has written about biomedical research and medical care as a journalist for The Atlanta Constitution, Kidney News, and DocGuide and as a communications strategist for Rockefeller University, Singapore's Biopolis and Fusionopolis, the American Society for Cell Biology and other leading research organizations. She is a member of the National Association of Science Writers.

ARTICLES BY CATHY YARBROUGH`

  • In Two Months, Gene Therapy Startup Raises $100 Million
    In Two Months, Gene Therapy Startup Raises $100 Million

    Generation Bio made its official debut in January 2018 after operating under-the-radar for over one year with $25 million in Series A financing from Atlas Venture. While in stealth mode, the company conducted the proof-of-concept studies on its gene therapy approach that would attract $100 million in Series B financing from new investors.

  • Intricate Supply Chain Complicates Gene Therapy Manufacturing
    Intricate Supply Chain Complicates Gene Therapy Manufacturing

    With the FDA’s approval of three new gene therapies, researchers and manufacturers must now figure out how streamline the development process.

  • Funding For Biopharmas Targeting Urgent Bacterial Threats
    Funding For Biopharmas Targeting Urgent Bacterial Threats

    A Nevada woman’s death in 2016 from an untreatable bacterial infection called attention to the possibility of an “antibiotic apocalypse,” when even the most deadly bacterial strains will prove resistant to all available antibiotics. “Antibiotic development is not keeping pace with the emergence of antibiotic-resistant bacterial strains,” said Kevin Outterson, executive director of the new global public-private partnership, Combatting Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).

  • Why Pet Health Is The Focus Of A New Biotech Sector
    Why Pet Health Is The Focus Of A New Biotech Sector

    For Aratana Therapeutics, 2016 was a banner year. The biotech company, founded in 2010, achieved FDA approvals for three of its 10 pipeline drugs. Last year the Kansas City-based company also forged a global partnership with the pharmaceutical giant Eli Lilly, a track record that any young biotech company would like to achieve.

  • Why An Investment Banker Returned To Drug Development

    Sandesh Seth was not considering leaving his position as head of healthcare investment banking at Laidlaw & Co. U.K. Ltd, when the board of small-cap biotech Actinium Pharmaceuticals asked him last year to serve as the company’s executive chairman.

  • Why Animal Health Is The Next Big Growth Area
    Why Animal Health Is The Next Big Growth Area

    Executives from Merial (the animal health division of Sanofi) and Zoetis discuss why the financial community is considering the animal health industry a promising short- and long-term investment opportunity.

  • Millennials Are Hard-Working And Dedicated. Really, They Are!
    Millennials Are Hard-Working And Dedicated. Really, They Are!

    Millennials, the single largest demographic in the workplace today, are often derided as lazy, disrespectful, and needy. They’re also criticized as being so addicted to technology that they email and text message information that should be communicated face-to-face to supervisors and coworkers.

  • Why Now Is The Time For Pharma To Expand Into Africa
    Why Now Is The Time For Pharma To Expand Into Africa

    “GSK is willing to make a small return now because we have a long-term view of the market potential of Africa,” says Allan Pamba, M.D., GSK’s VP of pharmaceuticals for East Africa and VP for government affairs for Africa.

  • From Windowless Data Room To The CEO’s Office
    From Windowless Data Room To The CEO’s Office

    Kurt Graves, the 47-year-old chairman, president, and CEO of Boston-based Intarcia Therapeutics, got his first major break in the life sciences industry 25 years ago as a sales representative for Merck in his home state of Michigan.

  • A Life Sciences Start-Up Learns To Pivot And Overcome Adversity
    A Life Sciences Start-Up Learns To Pivot And Overcome Adversity

    Jonathan Lim, M.D., was only 31 years old when he was appointed Halozyme Therapeutics’ first president and CEO in 2003. During the previous two years, he was a management consultant at McKinsey & Company, advising C-suite executives of both start-ups and Fortune 500 companies in the healthcare industry. But, prior to Halozyme, which is headquartered in San Diego, Lim had not worked at a biotech or pharmaceutical company.

More From Cathy Yarbrough`